(AOF) – Sanofi has announced the launch of the Euroapi listing project on Euronext Paris. The Board of Directors of the pharmaceutical group has decided to submit to its shareholders the decision to distribute approximately 58% of the share capital of Euroapi during the Ordinary and Extraordinary General Meeting of May 3, 2022. In the event of a favorable vote by the shareholders, the distribution will take place in the days following the admission of the Euroapi shares to the regulated market of Euronext Paris, subject to approval by the Autorité des Marchés Financiers (AMF).
Euroapi will be listed on Euronext Paris in the first half of 2022 despite volatile market conditions.
The French State, through the French Tech Souveraineté fund, plans to acquire 12% of the capital of Euroapi for a maximum amount of 150 million euros from Sanofi to become a long-term reference shareholder.
As expected, the pharmaceutical group will retain approximately 30% of Euroapi after the operation.
A specialist in the development, manufacture and marketing of active pharmaceutical ingredients, Euroapi expects to achieve consolidated sales of approximately €1 billion for the financial year ended December 31, 2022. Sanofi represented nearly half of Euroapi’s turnover in 2021.
The entire operation is subject to the approval of Sanofi’s 2022 General Meeting of Shareholders and the approval by the AMF of the Euroapi prospectus.
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an amount of credits (7 billion euros) never reached: 1.5 billion for hospital-university research, 2 billion for investment in health via bpi france , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenditure reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in the turnover of laboratories,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the medical benefit rendered is sufficient.